Navigating Novel Allogeneic Immunotherapy Approaches in Hematologic Malignancies

Sagar S. Patel, MD, discusses data from trials evaluating agents in the Orca platform and where they fit into hematologic malignancy treatment paradigms.

An analysis showed the manufacturing and distribution of Orca-T was consistent for patients with hematologic malignancies.

Orca-T improved clinical outcomes both overall and across patient subgroups with varied demographic and clinical features in the Precision-T trial.

Orca-T plus allogeneic CAR T-cell therapy may represent a rational treatment approach in high-risk B-cell malignancies.

Orca-T given with reduced intensity conditioning led to robust myeloid/T-cell engraftment and low rates of acute GVHD in hematologic malignancies.

Myeloablative Orca-Q demonstrated efficacy and safety in high-risk hematologic malignancies.